Longer-last­ing Botox com­peti­tor nabs FDA ap­proval — can it com­pete with Ab­b­Vie's $2B cash cow?

Re­vance Ther­a­peu­tics an­nounced Thurs­day that its first FDA ap­proval has fi­nal­ly ar­rived for its Botox com­peti­tor, known as Daxxi­fy, af­ter ini­tial­ly sub­mit­ting its orig­i­nal BLA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER